TPG Explores $5B Sale of Healthcare Payments Software Firm Lyric

TPG is reportedly exploring a significant divestiture, considering the sale of its healthcare payments integrity software business, Lyric, for an estimated $5 billion. The private equity giant has engaged JPMorgan to manage the potential transaction, though sources close to the matter emphasize that discussions are in their nascent stages and a deal is not guaranteed.

Lyric, formerly known as ClaimsXten, specializes in providing crucial technology that enables health insurers to scrutinize and prevent erroneous or improper medical claim disbursements. Its robust platform serves major industry players including UnitedHealth, CVS, and Humana, underscoring its critical role in the complex healthcare payment ecosystem. The company's financial performance is robust, with annual EBITDA reported to be around $250 million, which, at an estimated 20x multiple, supports the substantial valuation being considered.

This potential exit marks a notable chapter for TPG's investment in the sector. The firm acquired the business, then operating as ClaimsXten, from Change Healthcare in 2022 for approximately $2.2 billion. This acquisition was part of a larger regulatory process, specifically addressing antitrust concerns related to UnitedHealth's then-pending $13 billion acquisition of Change Healthcare. Following the acquisition, TPG rebranded the entity to Lyric in 2023, signaling a new phase of growth and strategic focus.

Since TPG's ownership, Lyric has reportedly experienced a substantial acceleration in revenue growth, although specific figures have not been publicly disclosed. The firm has consistently highlighted the company's strategic deployment of artificial intelligence and its extensive data assets as key drivers for future innovation and market advantage. This focus on AI aligns with broader industry trends where advanced analytics and machine learning are increasingly vital for optimizing operational efficiency and identifying new revenue streams within the healthcare sector.

However, the rapidly evolving artificial intelligence landscape presents a complex backdrop for this potential sale. Prospective buyers are increasingly evaluating how AI-native solutions might disrupt established software providers, potentially offering similar functionalities at a reduced cost. This dynamic could influence valuation benchmarks for companies in areas like claims management and payment integrity, prompting careful consideration of long-term competitive positioning and technological adaptability.

The healthcare technology sector continues to attract significant investor interest, driven by the ongoing digital transformation within healthcare systems. Companies that can demonstrate clear value in cost reduction, fraud prevention, and improved administrative efficiency are particularly attractive. Lyric's established market position and its focus on these critical areas position it as a compelling asset, even amidst evolving technological considerations.